论文部分内容阅读
为了解阿伦膦酸盐对骨密度的影响及其安全性和耐受性,对20名绝经后骨质疏松的妇女中进行阿伦膦酸盐(alendronate)10mg/天和安慰剂的随机、双盲、前瞻性研究,为期一年。结果显示,1年后阿伦膦酸盐组与安慰剂组相比,骨密度平均增长率:椎骨分别为4.87%与-0.23%;股骨颈分别为6.89%与-1.84%,(P<0.05)。副反应仅为轻微胃肠道反应。结论:阿伦膦酸盐能有效增加骨密度,且药物安全,耐受性好
To understand the effect of alendronate on bone mineral density and its safety and tolerability, 20 randomized, randomized, placebo-controlled, alendronate 10 mg / day and placebo in 20 postmenopausal women with osteoporosis, Double-blind, prospective study for one year. The results showed that after 1 year, the mean growth rate of bone mineral density in the alendronate group was 4.87% and -0.23% respectively compared with the placebo group; the femoral neck was 6.89% and -1 .84%, (P <0.05). Side effects are only mild gastrointestinal reactions. Conclusion: Alendronate can effectively increase the bone mineral density, and the drug is safe and well tolerated